European hivhep workshop 2018 – Presentations


 Paredes, Roger  2016 120The role of the human microbiome on HIV infection
(Not available)
Roger Paredes, MD, PhD, Irsi Caixa Foundation, Barcelona, Spain
 Session 1 - The future of the HIV epidemic in Europe
 Sandulescu, Oana_ 2016websiteThe HIV epidemic in CEE countries
Oana Sandulescu, MD, PhD, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
 Paraskevis, Dimitrios 2018 120x160HIV transmission in the migrant population
Dimitrios Paraskevis, PhD, National and Kapodistrian University of Athens Medical School, Athens, Greece
 van de Vijver, David 120x160How would the epidemic evolve in the future?
David van de Vijver, PharmD, PhD, Erasmus Medical Center, Rotterdam, the Netherlands
 Special session - Improving Drug Delivery for Sustained Treatment Success
 Khoo, Saye 2012Improving Drug Delivery: what are the new technologies?
(Not yet available)

Saye Khoo, MD, PhD, University of Liverpool, Liverpool, United Kingdom
 Pozniak, Anton 2013Long Acting HIV Drugs for Treatment: what are the data?
(Not yet available)

Anton Pozniak, MD, FRCP, Chelsea and Westminster Hospital, London, United Kingdom
 Coll, Pep 2016Long Acting HIV Drugs for Prevention: what are the data?
Pep Coll, MD, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
 Session 2 - Molecular epidemiology of HIV and Hepatitis
 Theys, Kristof 2018A new wild-type in the era of transmitted drug resistance
Kristof Theys, PhD, University of Leuven, Belgium
 Abstract-driven presentations
 Molecular surveillance reveals a recent outbreak of HIV-1 subtype C infections among people who inject drugs (PWID) in Munich, Germany
(Not available)
Norbert Bannert
 Is there a need for HCV resistance testing in routine diagnostics and patient treatment? - Routine HCV genotyping and resistance testing and performance of the Sentosa SQ HCV Genotyping v2.0 assay
Robert Ehret
 Prevalence of HCV resistance associated substitutions in Europe
Stephanie Popping, MD
 Session 3 - The roll-out of PrEP
 Coll, Pep 2016The current status of PrEP in Europe
Pep Coll, MD, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
 Harrigan, Richard 2012_120Influence of resistance in the future
Richard Harrigan, MD, PhD, BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
 Ghosn Jade, 2018Risk compensation in STDs
(Not available)

Jade Ghosn, MD, PhD, Hotel-Dieu University Hospital, Paris, France

THURSDAY, MAY 31, 2018

 Session 4 - Abstract-driven presentations
 Abstract-driven presentations
 A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors
Quentin le Hingrat
 Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study
Alexander Thielen
 Historical genotype predicts virological failure in HIV+ patients with low level viremia: A retrospective study from the ARCA cohort
F. Lombardi
 Dynamics of HIV DNA populations before and after transplantation with CCR5d32 stem cells
(Not yet available)
Annemarie Wensing, MD, PhD
 Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings
Maria Santoro
 Characterization of virological failure in HIV-1 infected patients switching to dual therapy with DTG plus one RTI (NRTI or NNRTI)
(Not available)
Nadia Gallizi
 Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo.
Jeroen van Kampen, MD, PhD
 Special session - Antiretroviral management: looking towards the horizon
 OLYMPUS DIGITAL CAMERAClinical trial data 3 vs 2 drug regimens
(Not yet available)
Andrea de Luca, MD, University of Siena, Siena, Italy
 Perno, Carlo Federico_120Longer term expectations around resistance
(Not yet available)
Carlo Perno, MD, PhD, University of Milan, Milan, Italy

Implications for clinical practice
(Not yet available)
Jonathan Schapiro, MD, National Hemophilia Center, Tel Aviv, Israel

 Session 5 - Roundtable Discussion: Bringing the next generation sequencing to the clinic
 Daeumer, Martin 2018New technologies reaching the clinic
Martin Daeumer, MSc, Institute of Immunology and Genetics, Kaiserlautern, Germany
 Novel simplified bioinformatics for NGS data analysis
Marc Noguera-Julian, PhD, irsiCaixa Foundation, Barcelona, Spain
 Session 6 - Management of Viral Hepatitis
 Ceccherini Silberstein, Francesca 2011_120Management of Hepatitis C therapy failures - Virological perspective
Francesca Ceccherini - Silbersteini, PhD, University of Rome "Tor Vergata", Italy
 Bhagani, Sanjay 2014_120Management of Hepatitis C therapy failures - Clinical perspective
Sanjay Bhagani, BSc FRCP, Royal Free Hospital, London, United Kingdom
 Berg, Thomas 2015Acute hepatitis A to E, Diagnosis and Management
Thomas Berg, MD, University Hospital Leipzig, Leipzig, Germany
 Abstract-driven presentations
 Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing
Slim Fourati
 Evaluation of pre-treatment risk factors associated with failure in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
S. Barbaliscia
 Can HBV-RNA be useful as a serological marker in patients with antiviral treatment? Presence of HBV-RNA and its correlation with other serological markers.
Maria Francesca Cortese

FRIDAY, JUNE 1, 2018

 Session 7 - What's in the pipeline? Presentations by scientists from the industry 
 Quercia, Romina 2018Pipeline Overview
(Not yet available)
Romina Quercia, MD, PhD
ViiV Healthcare, United Kingdom

Overview of Merck HIV Research and Development
(Not yet available)
Kathleen Squires, MD
Merck, USA

 White, Kristen 2018B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
Kirsten White, PhD
Gilead Sciences, USA
 Ibalizumab for the Treatment of Multidrug Resistant (MDR) HIV-1 Infection
(Not available)
Brinda Emu, MD
Theratechnologies / TaiMed Biologics, Yale School of Medicine, USA
 Steens,  Jean-Marc 2018Clinical Development of ABX464, drug candidate for HIV Functional Cure
Jean-Marc Steens, MD

Abivax, France
 Session 8 - Novel therapeutic strategies & prospects for cure
 OLYMPUS DIGITAL CAMERAReduced drug regimens
Andrea De Luca, MD, University of Siena, Italy
 Blanco, Julian 2017What is the place of monoclonal antibodies in the clinic
Julià Blanco, PhD, IrsiCaixa Foundation, Barcelona, Spain
 Wensing, Annemarie 2017 120Prospects for cure
(Not yet available)

Annemarie Wensing, MD, PhD, University Medical Center Utrecht, Utrecht, The Netherlands